Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

severe hypertriglyceridemia

- PMLiVE

AZ takes severe asthma antibody into phase III

Benralizumab shows promise in clinical trials

- PMLiVE

FDA raises awareness of misleading drug ads

E-learning course to help HCPS and students learn how to report untruthful promotion

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

- PMLiVE

Gilead’s sofosbuvir aces FDA advisory committee

On track for hepatitis C approval in US

- PMLiVE

J&J wins FDA panel backing for hepatitis C drug

Simeprevir would challenge Victrelis and Incivek if approved

- PMLiVE

AstraZeneca to close UK environmental lab

Decision on Brixham facility in Devon puts 71 positions at risk

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

- PMLiVE

FDA sets up rare disease research fund

Will invest $14m across 15 orphan drug projects

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

Actelion HQ Switzerland

Actelion gets US green light for new PAH drug Opsumit

Approval will help reduce impact of generic competition for Tracleer

- PMLiVE

Amarin slides as FDA panel votes against fish oil therapy

Advisory committee wants more data on Vascepa

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links